Transo-Pharm Expands Portfolio - Welcome on board, Norepinephrine Bitartrate

Epinephrine Base and Epinephrine Bitartrate have been in our portfolio even before we acquired the IP from the originator Boehringer Ingelheim. Over the last couple of years our customers have expressed their need for Norepinephrine Bitartrate and we listened.
 
We have proudly partnered up with hameln rds s.r.o. a Slovakian based API producer who has developed a robust Norepinephrine production process. The CEP has been issued by EDQM July 26, 2024. In this partnership, Transo-Pharm will focus on all commercial aspects and hameln rds will concentrate on production and quality.

These APIs have distinct roles: Epinephrine impacts the heart and is crucial for treating anaphylaxis, cardiac arrest, and severe asthma attacks. Norepinephrine on the other hand affects blood vessels and is used to address dangerously low blood pressure.
 
Both actives are crucial, emergency drugs substances. This addition is pivotal for healthcare professionals seeking comprehensive life-saving treatment options.
 
Norepinephrine Bitartrate perfectly fits to Transo-Pharm and our customers!